Costs and quality of life of patients with multiple sclerosis in Europe

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 8, 2006, Pages 918-926

  Kobelt, G ^a,b   Berg, J ^c   Lindgren, P ^c   Fredrikson, S ^d   Jonsson B ^e  

^a European Health Economics ^*  (France)

^b LUND UNIVERSITY   (Sweden)

^c STOCKHOLM HEALTH ECONOMICS   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COST OF ILLNESS; DEMOGRAPHY; DISEASE SEVERITY; EUROPE; EXPANDED DISABILITY STATUS SCALE; FAMILY COUNSELING; FEMALE; FOLLOW UP; HEALTH CARE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL SOCIETY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RELAPSE; RESOURCE ALLOCATION; WORK CAPACITY; CROSS-SECTIONAL STUDY; ECONOMICS; EMPLOYMENT; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH SURVEY; HOSPITALIZATION; MIDDLE AGED; RECURRENT DISEASE; STATISTICS; UTILIZATION REVIEW;

ADULT; CROSS-SECTIONAL STUDIES; EMPLOYMENT; EUROPE; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; QUALITY OF LIFE; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 33746316226     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.090365     Document Type: Article

References (27)

1. Parkin D, Jacoby A, McNamee P. Treatment of multiple sclerosis with interferon beta-1b: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000;68:144-9.
2. Forbes RB, Lees A, Waugh N, et al. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ 1999;319:1529-33.
3. Kobelt G, Jönsson L, Henriksson F, et al. Cost-utility of interferon beta-1b in secondary progressive multiple sclerosis. Int J Technol Assess Health Care 2000;16:768-80.
4. Kobelt G, Jönsson L, Miltenburger C. Cost-utility analysis of interferon-beta-1b in secondary progressive multiple sclerosis, using natural history disease data. Int J Technol Assess Health Care 2002;18:127-38.
5. Kobelt G, Jönsson L, Fredrikson S. A new disease model to estimate the cost of disease progression for different types of MS and different subgroups of patients. Eur J Health Econ 2003;4:50-9.
6. Nuijten M, Hutton J. Cost-effectiveness of beta interferon in multiple sclerosis: a Markov process analysis. Value Health 2002;5:44-54.
7. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003;326:522-8.
8. LePen C, Coyle P, Vollmer T, et al. Long-term cost effectiveness of interferon-beta-1a in the treatment of relapsing remitting multiple sclerosis. Clin Drug Invest 2003;23:571-81.
9. Prosser L, Kuntz K, Bar-Or A, et al. Cost effectiveness of interferon beta-1a, interferon beta-1b and glatiramer acetate in newly diagnosed non primary progressive multiple sclerosis. Value Health 2004;7:554-68.
10. Blumhardt L, Wood C. The economics of multiple sclerosis: a cost of illness study. Br J Med Econ 1996;10:99-118.
11. Holmes J, Madgwick T, Bates D. The cost of multiple sclerosis. Br J Med Econ 1995;8:181-93.
12. Henriksson F, Jönsson B. The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 1998;13:597-606.
13. Carton H, Loos R, Pacolet J, et al. Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). J Neurol Neurosurg Psychiatry 1998;64:444-50.
14. Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002;249:152-63.
15. Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis. A cross-sectional study in Sweden, Eur J Neurol 2001;8:27-35.
16. Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. Stockholm: Stockholm School of Economics, 2000.
17. Russo P, Capone A, Paolillo A, et al. Cost analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Invest 2004;24:409-20.
18. Kazas E, Grisouard R, Zanni J, et al. Multiple sclerosis treatment with interferon beta: prevalence and cost of the public health fund in 2000. Rev Méd Assurance Maladie 2003;34:147-56.
19. Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in Germany. Eur J Health Econ 2001;2:60-8.
20. Kobelt G, Berg J, Atherley D, et al. Cost and quality of life in multiple sclerosis. A cross-sectional study in the USA, EFI Research Report Number 594. Stockholm: Stockholm School of Economics, 2005.
21. Kurtzke J. Rating neurological impairment in multiple sclerosis and Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52.
22. Hohol M, Orav E, Weiner H. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 1995;45:251-5.
23. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
24. Dolan P, Gudex C, Kind P, et al. A social tariff for EuroQol: results from a UK general population survey, Discussion Paper Number 138. York: Centre for Health Economics, University of York, 1995.
25. Torrance G. Measurement of health state utilities for economic appraisal. A review. J Health Econ 1986;5:1-30.
26. Koopmansschap M, Rutten F, van Ineveld B, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89.
27. Eichler H, Kong S, Gerth WC, et al. Use of cost-effectiveness analysis in health care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28.